Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (PRCT) ® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

DUBLIN, Aug. 25, 2025 /PRNewswire/ -- ProVerum Limited, the developer of the ProVee® System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH), announced today the ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

TORONTO, Oct 2 (Reuters) - A new management team at AEterna Zentaris put its stamp on the Canadian biotechnology company on Tuesday, unveiling a strategic plan that includes commercialization of its ...

Our extensive research on the Benign Prostatic Hyperplasia Treatment (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, in ...